American Society of Hematology (ASH)

Study Moves CAR-T Therapy Forward in Myeloma

Presented as a late-breaking abstract, CANDOR met its primary end point, showing that daratumumab/carfilzomib/dexamethasone significantly prolonged progression-free survival. Read More ›

In Routine Practice, Ixazomib Regimen Mirrors Efficacy of Clinical Trial

Responses were achieved by more than 90% of patients receiving JNJ-4528, and all patients tested for minimal residual disease (MRD) status were MRD-negative. Read More ›

In an analysis of more than 10,000 relapsed/refractory patients treated in routine clinical practice with ixazomib/lenalidomide/dexamethasone, outcomes were as good as those reported in clinical trials. Read More ›

What is Minimal Residual Disease (MRD) Negativity?

In Relapsed or Refractory Myeloma, Addition of Elotuzumab to Lenalidomide + Dexamethasone Improves Outcomes with No Detriment to Quality of Life

Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients. Read More ›

Final analysis of patient-reported outcomes from the phase 3 ELOQUENT-2 trial confirms elotuzumab has no negative impact on health-related quality of life. Read More ›

Multiple Myeloma as a Chronic Disease

As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients. Read More ›

Triplets versus Quads

Adding Elotuzumab to Pomalidomide, Bortezomib, and Dexamethasone Leads to Promising Responses in Relapsed/Refractory Multiple Myeloma

Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma. Read More ›

COLUMBA Update: Subcutaneous Daratumumab Shows Similar Efficacy to IV Formulation in Relapsed/Refractory Multiple Myeloma, with Fewer Adverse Events

In patients with relapsed/refractory multiple myeloma, treatment with elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone shows encouraging responses, with manageable toxicity. Read More ›

Compared with intravenous (IV) administration, subcutaneous daratumumab led to similar response rates with fewer infusion-related reactions. Read More ›

CAR T-Cell Data in Multiple Myeloma